Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen

Journal of Neuroimmunology

Volumn 206, Issue 1-2, 2009, Pages 5-13

  Mignini, Fiorenzo ^a   Tomassoni, Daniele ^a   Traini, Enea ^a   Amenta, Francesco ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Dopamine receptors; Dopamine transporter; Immunohistochemistry; Lymphoid organ; Vesicular monoamine transporter; Western blot analysis

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DOPAMINERGIC SYSTEM; IMMUNOCHEMISTRY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROENVIRONMENT; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETICULAR FORMATION; SPLEEN; THYMOCYTE; WISTAR RAT;

ANIMALS; BLOTTING, WESTERN; DOPAMINE; IMMUNOHISTOCHEMISTRY; MALE; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPLEEN; THYMUS GLAND; VESICULAR TRANSPORT PROTEINS;

EID: 58149265242     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.09.018     Document Type: Article

References (49)

1. Adachi S., and Iwata M. Duration of calcineurin and Erk signals regulates CD4/CD8 lineage commitment of thymocytes. Cell. Immunol. 215 (2002) 45-53
2. Ader D., Cohen D., and Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet 345 (1995) 99-103
3. Amenta F., Bronzetti E., Cantalamessa F., El-Assouad D., Felici L., Ricci A., and Tayebati S.K. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J. Neuroimmunol. 117 (2001) 133-142
4. 3H]GBR 12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex. J. Neurochem. 48 (1987) 1887-1896
5. Carlsson A. Perspectives on the discovery of central monoaminergic neurotransmission. Annu. Rev. Neurosci. 10 (1987) 19-40
6. Caronti B., Calderaro C., Passarelli F., Palladini G., and Pontieri F.E. Dopamine receptor mRNAs in the rat lymphocytes. Life Sci. 62 (1998) 1919-1925
7. Cook-Mills J.M., Cohen R.L., Perlman R.L., and Chambers D.A. Inhibition of lymphocytes activation by catecholamines: evidence for a non-classical mechanism of catecholamine action. Immunology 85 (1995) 544-549
8. Dal Toso R., Sommer B., Ewert M., Herb A., Pritchett D.B., Bach A., Shivers B.D., and Seeburg P.H. The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J. 8 (1989) 4025-4034
9. Fei H., Grygoruk A., Brooks E.S., Chen A., and Krantz D.E. Trafficking of vesicular neurotransmitter transporters. Traffic. 9 (2008) 1425-1436
10. Gingrich J.A., and Caron M.G. Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16 (1993) 299-321
11. Giros B., and Caron M.G. Molecular characterization of the dopamine transporters. Trends Pharmacol Sci. 14 (1993) 43-49
12. Giros B., Sokoloff P., Martres M.P., Riou J.F., Emorine L.J., and Schwartz J.C. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 342 (1989) 923-926
13. Gordon J., and Barnes N.M. Lymphocytes transport serotonin and dopamine: agony or ecstasy?. Trends Immunol. 24 (2003) 438-443
14. Hansson S.R., Mezey E., and Hoffman B.J. Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. II. Expression in neural crest derivatives and their target sites in the rat. Brain Res. Dev. Brain Res. 110 (1998) 159-174
15. Hayday A.C., and Pennington D.J. Key factors in the organized chaos of early T cell development. Nat. Immunol. 8 (2007) 137-144
16. 3H]GBR 12935 binding in the human and rat frontal cortex. J. Neurochem. 56 (1991) 1663-1672
17. Ilani T., Strous R.D., and Fuchs S. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J. 18 (2004) 1600-1602
18. Jaubert A., Ichas F., and Bresson-Bepoldin L. Signaling pathway involved in the pro-apoptotic effect of dopamine in the GH3 pituitary cell line. Neuroendocrinology 83 (2006) 77-88
19. Katz D.M., Adler J.E., and Black I.B. Catecholaminergic primary sensory neurons: autonomic targets and mechanisms of transmitter regulation. Fed. Proc. 46 (1987) 24-29
20. Kavelaars A., Cobelens P.M., Teunis M.A.T., and Heijnen C.J. Changes in innate and acquired immune responses in mice with targeted deletion of the dopamine transporter gene. J. Neuroimmunol. 161 (2005) 162-168
21. Kohm A.P., and Sanders V.M. Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol Rev. 53 (2001) 487-525
22. Levitt P., Harvey J.A., Friedman E., Simansky K., and Murphy E.H. New evidence for neurotransmitter influences on brain development. Trends Neurosci. 20 (1997) 269-274
23. Lopes-Carvalho T., Foote J., and Kearney J.F. Marginal zone B cells in lymphocyte activation and regulation. Curr. Opin. Immunol. 17 (2005) 244-250
24. Masson J., Sagne C., Hamon M., and El Mestikawy S. Neurotransmitter transporters in the central nervous system. Pharmacol. Rev. 51 (1999) 439-464
25. Meredith E.J., Chamba A., Holder M.J., Barnes M.N., and Gordon J. Close encounters of the monoamine kind: immune cells betray their nervous disposition. Immunology 115 (2005) 289-295
26. Mignini F., Streccioni V., and Amenta F. Autonomic Innervation of immune organs and neuroimmune modulation. Auton. Autacoid Pharmacol. 23 (2003) 1-25
27. Mignini F., Traini E., Tomassoni D., and Amenta F. Dopamine plasma membrane transporter (DAT) in rat thymus and spleen: an immunochemical and immunohistochemical study. Auton. Autacoid Pharmacol. 26 (2006) 183-189
28. Monsma Jr. F.J., McVittie L.D., Gerfen C.R., Mahan L.C., and Sibley D.R. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 342 (1989) 926-929
29. Neilson J.R., Winslow M.M., Hur E.M., and Crabtree G.R. Calcineurin B1 is essential for positive but not negative selection during thymocyte development. Immunity 20 (2004) 255-266
30. 3H] GBR 12935 binding proteins. Arch. Biochem. Biophys. 276 (1995) 424-432
31. Oberbeck R. Catecholamines: physiological immunomodulators during health and illness. Curr. Med. Chem. 13 (2006) 1979-1989
32. Offen D., Ziv I., Gorodin S., Barzilai A., Malik Z., and Melamed E. Dopamine-induced programmed cell death in mouse thymocytes. Biochim. Biophys. Acta. 31 (1995) 171-177
33. Olanow C.W. The pathogenesis of cell death in Parkinson's disease-2007. Mov. Disord. 22 (2007) 335-342
34. Pezzano M., Samms M., Martinez M., and Guyden J. Questionable thymic nurse cell (2001). Microbiol. Mol. Biol. Rev. 65 (2001) 390-403
35. Pilipović I., Vidić-Danković B., Perišić M., Radojević K., Čolić M., Todorović V., and Leposavić G. Sexual dimorphism in the catecholamine-containing thymus microenvironment: a role for gonadal hormones. J. Neuroimmunol. 195 (2008) 7-20
36. Qiu Y., Peng Y., and Wang J. Immunoregolatory role of neurotransmitter. Adv. Neuroimmunol. 6 (1996) 223-231
37. Sherren N., and Pappas B.A. Selective acetylcholine and dopamine lesions in neonatal rats produce distinct patterns of cortical dendritic atrophy in adulthood. Neuroscience 136 (2005) 445-456
38. Sibley D.R., and Monsma Jr. F.J. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13 (1992) 61-69
39. Sklar L.S., and Anisman H. Stress and cancer. Psychol. Bull. 89 (1981) 369-406
40. Swarzenski B.C., Tang L., Oh Y.J., O'Malley K.L., and Todd R.D. Morphogenic potentials of D2, D3, and D4 dopamine receptors revealed in transfected neuronal cell lines. Proc. Natl. Acad. Sci. U. S. A. 18 (1994) 649-653
41. Takeuchi Y., and Fukunaga K. Differential subcellular localization of two dopamine D2 receptor isoforms in transfected NG108-15 cells. J. Neurochem. 85 (2003) 1064-1074
42. Tsao C.W., Lin Y.S., and Cheng J.T. Effect of dopamine on immune cell proliferation in mice. Life Sci. 61 (1997) 361-371
43. Vaughan R.A., Uhl G.R., and Kuhar M.J. Dopamine transporter recognition by antipeptide antibodies. Cell. Mol. Neurosci. 4 (1993) 209-215
44. Volz T.J., Hanson G.R., and Fleckenstein A.E. Kinetic analysis of developmental changes in vesicular monoamine transporter-2 function. Synapse 60 (2006) 474-477
45. Wang S.L., Kutsche M., DiSciullo G., Schachner M., and Bogen S.A. Selective malformation of the splenic white pulp border in L1-deficient mice. J. Immunol. 165 (2000) 2465-2473
46. Wolfe S.E., and Morris S.J. Dopamine D2 receptor isoforms expressed in AtT20 cells differentially couple to G proteins to acutely inhibit high voltage-activated calcium channels. J. Neurochem. 73 (1999) 2375-2382
47. Xia X.G., Schmidt N., Teismann P., Ferger B., and Schulz J.B. Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. J. Neurochem. 79 (2001) 63-70
48. Yang C.Y., Lukasiewicz P., Maguire G., Werblin F.S., and Yazulla S. Amacrine cells in the tiger salamander retina: morphology, physiology, and neurotransmitter identification. J. Comp. Neurol. 312 (1991) 19-32
49. Zheng G., Dwoskin L.P., and Crooks P.A. Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 8 (2006) E682-E692